Assessing the Preclinical Efficacy of Combined Ferroptotic Agent and Secretory TRAIL-Armed NK Cells for Pseudomyxoma Peritonei
Abstract
Pseudomyxoma peritonei (PMP) is a rare cancer with an estimated incidence of 12 out of a million. It usually starts in the appendix. Sometimes it starts in another part of the bowel, the bladder, or the ovaries, but this is rare. Clinically, PMP usually presents with a variety of unspecific signs and symptoms, including abdominal pain and distention, ascites, or even bowel obstruction. Over the past two decades, oncologists have introduced extensive cytoreductive surgery (CRS) followed by hyperthermic intraperitoneal chemotherapy (HIPEC) as a novel treatment. Although CRS with HIPEC has become the treatment of choice for respectable PMP and has improved the survival of these patients, complete responses have been rare, and recurrences are common due to remaining residual microscopic disease. Thus, we need to develop a novel second-line therapy to improve the efficacy of current PMP therapy.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2023
- Accession Number
- AD1216870
Entities
People
- Yong J Lee
Organizations
- Cedars-Sinai Medical Center